Share on LinkedInShare on LinkedIn

ARTICLE · 05 MAY 2015

SCC Highlights The Class Action Risk Arising From Regulatory Action

The recent decision of the Supreme Court of Canada in Theratechnologies Inc. v. 121851 Canada Inc. raises interesting questions about disclosure obligations that can be triggered by a regulator’s inquiries, and resulting class action risk if disclosure is inadequate.

CanadaLitigation, Mediation & Arbitration

The recent decision of the Supreme Court of Canada inTheratechnologies Inc. v. 121851 Canada Inc. raises interesting questions about disclosure obligations that can be triggered by a regulator's inquiries, and resulting class action risk if disclosure is inadequate.

The case arose as a proposed class action brought by shareholders of Theratechnologies Inc. ("Thera") . The plaintiff alleged that Thera failed to adequately disclose and respond to questions that it received from the FDA as part of the regulatory approval process for a new drug. The FDA questions were about side effects of a proposed new drug. When the questions were publicized externally, Thera's stock dropped by 58% that same day.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from